Global Arthritis Monoclonal Antibodies Market Report 2024

Arthritis Monoclonal Antibodies Global Market Report 2024 – By Drug (Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima), By Application (Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Other Applications), By End-Use (Hospitals, Research Institutes, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033

Starting Price : $5000.00 | Pages : 250 | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Arthritis Monoclonal Antibodies Market

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Arthritis Monoclonal Antibodies Market Definition And Segments

Arthritis monoclonal antibodies refer to a class of sophisticated and useful biological medicines used to treat rheumatoid arthritis and other immune-mediated inflammatory conditions. They inhibit the inflammatory protein interleukin-6, which reduces arthritis-related joint pain and swelling as well as other inflammation-related symptoms. To prevent the body from rejecting the new organ after surgery, they reduce the body's defense mechanism.

The main types of drugs in arthritis monoclonal antibodies are Remicade, humira, enbrel, Rituxan, orencia, actemra, simponi, Cinzia, and Remsima. REMICADE is a prescription drug for persons with slightly too severely active Crohn's disease who haven't had success with other treatments. The different applications include rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, and others, and involve various sectors such as hospitals, research institutes, and others.

The arthritis monoclonal antibodies market covered in this report is segmented –

1) By Drug: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima

2) By Application: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Other Applications

3) By End-Use: Hospitals, Research Institutes, Other End-Users

The arthritis monoclonal antibodies market size has grown strongly in recent years. It will grow from $58.09 billion in 2023 to $62.29 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to the rising prevalence of arthritis, increasing awareness of arthritis monoclonal antibodies, expanding the range of approved arthritis monoclonal antibodies, government support for research and development, and increased investment from pharmaceutical companies.

The arthritis monoclonal antibodies market size is expected to see strongly grown in the next few years. It will grow to $83.76 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to combination therapies, expanding indications, patient preference, and increased healthcare spending. Major trends in the forecast period include biosimilars and biobetters, targeted therapies, homecare administration, real-world evidence, cost and access considerations, and advancements in drug delivery.

Arthritis Prevalence Fuels Growth In Arthritis Monoclonal Antibody Market

The increasing prevalence of arthritis globally has contributed to the growth of the arthritis monoclonal antibody market. According to the Global RA Network, in 2021, Over 350 million individuals worldwide suffer from arthritis and osteoarthritis is the most common form of arthritis followed by gout, fibromyalgia, and rheumatoid arthritis. According to WHO, the prevalence of rheumatoid arthritis varies between 0.3% and 1%, and the worldwide estimates of osteoarthritis include 9.6% of men and 18% of women. The increased prevalence of arthritis is driving the growth of the arthritis monoclonal antibody market.

Rising Approvals For Personalized Medicines Are Anticipated To Fuel The Growth Of The Arthritis Monoclonal Antibody Market

The rising approvals for personalized medicines are expected to propel the arthritis monoclonal antibody market going forward. Personalized medicines refer to therapeutic products or treatments tailored to the individual patient. They are designed based on a patient's genetic, biomarker, phenotypic, or psychosocial characteristics that can predict an individual's response to a treatment. Monoclonal antibodies (mABs) are the latest generation of drugs that fit the personalized medicine paradigm and have the potential to improve patient outcomes and efficiency in healthcare. For instance, in 2021, according to The Personalized Medicine Coalition, a U.S.- organization promoting the adoption of personalized medicine, the FDA's CDER approved 50 new molecular entities (NMEs), out of which 17 (35%) were classified as personalized medicines by the Personalized Medicine Coalition. Therefore, the rising approvals for personalized medicines drive the anatomical pathology equipment and consumables market. Therefore, the rising approvals for personalized medicines drive the arthritis monoclonal antibody market.

Major companies operating in the arthritis monoclonal antibodies market include Johnson & Johnson, Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., Genentech Inc., GlaxoSmithKline plc., AstraZeneca PLC, Mylan N.V., Bristol Myers Squibb, Eli Lilly and Company, Thermo Fisher Scientific Inc., Sanofi SA, Novo Nordisk A/S, Daiichi Sankyo Company Ltd., Seattle Genetics, Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Corp., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., HanAll Biopharma Co. Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Regeneron Pharmaceuticals Inc., Samsung Bioepis Co. Ltd.

High Costs Of Monoclonal Antibodies Pose Challenges To Arthritis Monoclonal Antibody Market

The high cost of monoclonal antibodies is expected to hamper the arthritis monoclonal antibody global market. According to the American Journal of Managed Care (AJMC), a survey was conducted to know the average price of monoclonal antibodies approved in the last 20 years by the FDA across disease states and found that the average annual price of 1-year treatment for each monoclonal antibody indication was $96,731. The high costs of these antibodies are basically due to the cost incurred in development and production. High costs of monoclonal antibodies are therefore expected to limit the market growth.

Advancements In Therapeutic Monoclonal Antibodies Revolutionize The Arthritis Treatment Landscape

The development of therapeutic monoclonal antibody products is becoming an indispensable tool in the development of the arthritis monoclonal antibody market. Monoclonal antibodies are more efficient than small molecules and peptides in the treatment of arthritis. These are target-specific and have good efficiency for disease treatment. These improved treatment options are evident with the launch of a greater number of monoclonal antibody drugs for arthritis.

New Version To Provide A Cheaper Alternatives

Major companies operating in the arthritis monoclonal antibody market are launching new biosimilar versions such as the Hulio to provide affordable treatment. Hulio is a biosimilar version of AbbVie's blockbuster rheumatoid arthritis drug, Humira. For instance, in July 2023, Biocon Biologics, an India-based subsidiary of Biocon Limited, focused on developing biosimilar therapies launched, the Hulio (adalimumab-fkjp), a biosimilar counterpart of Humira. This monoclonal antibody, used for conditions like rheumatoid arthritis and psoriatic arthritis, is priced 5% lower than Humira, which is currently listed at $6,922 per carton.

Abiogen Pharma Spa Acquired EffRx Pharmaceuticals Sa

In May 2023, Abiogen Pharma Spa, an Italy-based pharmaceutical company, acquired EffRx Pharmaceuticals SA for $8.77 million. The acquisition of a majority stake in EffRx is consistent with Abiogen's growth strategy. It provides a springboard for their international expansion and affirms their dedication to improving osteoarticular and bone metabolism diseases. EffRx Pharmaceuticals SA is a Switzerland-based pharmaceutical company involved in treating various disorders, including arthritis.

North America was the largest region in the arthritis monoclonal antibodies market in 2023. The regions covered in the arthritis monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the arthritis monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The arthritis monoclonal antibodies market consists of sales of infliximab, adalimumab, golimumab, and certolizumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The arthritis monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides arthritis monoclonal antibodies market statistics, including arthritis monoclonal antibodies industry global market size, regional shares, competitors with arthritis monoclonal antibodies market share, detailed arthritis monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the arthritis monoclonal antibodies industry. This arthritis monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Arthritis Monoclonal Antibodies Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $62.29 billion
Revenue Forecast In 2033 $83.76 billion
Growth Rate CAGR of 7.7% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Drug: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima
2) By Application: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Other Applications
3) By End-Use: Hospitals, Research Institutes, Other End-Users
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Johnson & Johnson; Hoffmann-La Roche Ltd.; Novartis AG; Pfizer Inc.; AbbVie Inc.; Amgen Inc.; Genentech Inc.; GlaxoSmithKline plc.; AstraZeneca plc; Mylan N.V.; Bristol Myers Squibb; Eli Lilly and Company; Thermo Fisher Scientific Inc.; Sanofi SA; Novo Nordisk A/S; Daiichi Sankyo Company Ltd.; Seattle Genetics; Teva Pharmaceutical Industries Ltd.; Shanghai Junshi Biosciences Co. Ltd.; GenScript Biotech Corporation; Sigma-Aldrich Co. LLC; AbGenomics Corp.; ADC Therapeutics SA; Agensys Inc.; Alexion Pharmaceuticals Inc.; ALMAC Group Ltd.; Ambrx Inc.; Astellas Pharma Inc.; Celgene Corporation; Celldex Therapeutics Inc.; Boehringer Ingelheim International GmbH; Celltrion Inc.; HanAll Biopharma Co. Ltd.; Merck & Co. Inc.; Mitsubishi Tanabe Pharma Corporation; Regeneron Pharmaceuticals Inc.; Samsung Bioepis Co. Ltd.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Arthritis Monoclonal Antibodies Market Characteristics

    3. Arthritis Monoclonal Antibodies Market Trends And Strategies

    4. Arthritis Monoclonal Antibodies Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On the Market

    4.2. Ukraine-Russia War Impact On the Market

    4.3. COVID-19 Impact On the Market

    5. Global Arthritis Monoclonal Antibodies Market Size and Growth

    5.1. Global Arthritis Monoclonal Antibodies Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Arthritis Monoclonal Antibodies Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Arthritis Monoclonal Antibodies Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Arthritis Monoclonal Antibodies Market Segmentation

    6.1. Global Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Remicade

    Humira

    Enbrel

    Rituxan

    Orencia

    Actemra

    Simponi

    Cimzia

    Remsima

    6.2. Global Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Rheumatoid Arthritis

    Osteoarthritis

    Psoriatic Arthritis

    Ankylosing Spondylitis

    Fibromyalgia

    Other Applications

    6.3. Global Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospitals

    Research Institutes

    Other End-Users

    7. Arthritis Monoclonal Antibodies Market Regional And Country Analysis

    7.1. Global Arthritis Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Arthritis Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Arthritis Monoclonal Antibodies Market

    8.1. Asia-Pacific Arthritis Monoclonal Antibodies Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Arthritis Monoclonal Antibodies Market

    9.1. China Arthritis Monoclonal Antibodies Market Overview

    9.2. China Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Arthritis Monoclonal Antibodies Market

    10.1. India Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Arthritis Monoclonal Antibodies Market

    11.1. Japan Arthritis Monoclonal Antibodies Market Overview

    11.2. Japan Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Arthritis Monoclonal Antibodies Market

    12.1. Australia Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Arthritis Monoclonal Antibodies Market

    13.1. Indonesia Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Arthritis Monoclonal Antibodies Market

    14.1. South Korea Arthritis Monoclonal Antibodies Market Overview

    14.2. South Korea Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Arthritis Monoclonal Antibodies Market

    15.1. Western Europe Arthritis Monoclonal Antibodies Market Overview

    15.2. Western Europe Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Arthritis Monoclonal Antibodies Market

    16.1. UK Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Arthritis Monoclonal Antibodies Market

    17.1. Germany Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Arthritis Monoclonal Antibodies Market

    18.5. France Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Arthritis Monoclonal Antibodies Market

    19.9. Italy Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Arthritis Monoclonal Antibodies Market

    20.13. Spain Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Arthritis Monoclonal Antibodies Market

    21.1. Eastern Europe Arthritis Monoclonal Antibodies Market Overview

    21.2. Eastern Europe Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Arthritis Monoclonal Antibodies Market

    22.1. Russia Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Arthritis Monoclonal Antibodies Market

    23.1. North America Arthritis Monoclonal Antibodies Market Overview

    23.2. North America Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Arthritis Monoclonal Antibodies Market

    24.1. USA Arthritis Monoclonal Antibodies Market Overview

    24.2. USA Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Arthritis Monoclonal Antibodies Market

    25.1. Canada Arthritis Monoclonal Antibodies Market Overview

    25.2. Canada Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Arthritis Monoclonal Antibodies Market

    26.1. South America Arthritis Monoclonal Antibodies Market Overview

    26.2. South America Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Arthritis Monoclonal Antibodies Market

    27.1. Brazil Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Arthritis Monoclonal Antibodies Market

    28.1. Middle East Arthritis Monoclonal Antibodies Market Overview

    28.2. Middle East Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Arthritis Monoclonal Antibodies Market

    29.1. Africa Arthritis Monoclonal Antibodies Market Overview

    29.2. Africa Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Arthritis Monoclonal Antibodies Market Competitive Landscape And Company Profiles

    30.1. Arthritis Monoclonal Antibodies Market Competitive Landscape

    30.2. Arthritis Monoclonal Antibodies Market Company Profiles

    30.2.1. Johnson & Johnson

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Hoffmann-La Roche Ltd.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Novartis AG

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Pfizer Inc.

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. AbbVie Inc

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Global Arthritis Monoclonal Antibodies Market Competitive Benchmarking

    32. Global Arthritis Monoclonal Antibodies Market Competitive Dashboard

    33. Key Mergers And Acquisitions In The Arthritis Monoclonal Antibodies Market

    34. Arthritis Monoclonal Antibodies Market Future Outlook and Potential Analysis

    34.1 Arthritis Monoclonal Antibodies Market In 2028 - Countries Offering Most New Opportunities

    34.2 Arthritis Monoclonal Antibodies Market In 2028 - Segments Offering Most New Opportunities

    34.3 Arthritis Monoclonal Antibodies Market In 2028 - Growth Strategies

    34.3.1 Market Trend Based Strategies

    34.3.2 Competitor Strategies

    35. Appendix

    35.1. Abbreviations

    35.2. Currencies

    35.3. Historic And Forecast Inflation Rates

    35.4. Research Inquiries

    35.5. The Business Research Company

    35.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Arthritis Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Arthritis Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Johnson & Johnson Financial Performance
  • Table 75: Hoffmann-La Roche Ltd. Financial Performance
  • Table 76: Novartis AG Financial Performance
  • Table 77: Pfizer Inc. Financial Performance
  • Table 78: AbbVie Inc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Arthritis Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Arthritis Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Arthritis Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Johnson & Johnson Financial Performance
  • Figure 75: Hoffmann-La Roche Ltd. Financial Performance
  • Figure 76: Novartis AG Financial Performance
  • Figure 77: Pfizer Inc. Financial Performance
  • Figure 78: AbbVie Inc Financial Performance
Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company
Read More
Global Gene Therapy Market 2022 – Market Opportunities And Strategies
Read More
The Microbiome Market Share, Market Size, And Growth Rate 2022
Read More
Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth
Read More
Orthobiologics Devices And Equipment Global Market Report 2024 – By Product Type (Demineralized Bone Matrix, Synthetic Bone Substitutes, Stem Cell Therapy, Plasma-Rich Protein, Viscosupplementation, Bone Morphogenetic Protein, Synthetic Orthobiologics), By Application (Osteoarthritis and Degenerative Arthritis, Soft-Tissue Injuries, Fracture Recovery, Maxillofacial and Dental Applications, Spinal Fusion, Trauma Repair, Reconstructive Surgery), By End Use (Hospitals, Orthopedic Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Microbiome Global Market Report 2024 – By Type (Bacteria, Archaea, Viruses, Other Microbiomes), By Product (Therapeutics, Diagnostics), By Technology (Genomics, Proteomics, Metabolomics), By End-Use (Infectious Diseases, Gastrointestinal Disorders, Metabolic Disorders, Cancers, Other Diseases) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Psoriatic Arthritis Treatment Global Market Report 2024 – By Drug Class (Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biologics, Other Drug Classes), By Route Of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2024-2033
View Report
TNF Alpha Inhibitors Global Market Report 2024 – By Drug (Remicade (Infliximab), Enbrel (Etanercept), Humira (Adalimumab), Cimzia (Certolizumab Pegol), Simponi (Golimumab)), By Route Of Administration (Oral, Subcutaneous, Intravenous, Other Route Of Administration), By Disease Type (Inflammatory Bowel Disease, Psoriatic Arthritis, Ulcerative Colitis (UC), Rheumatoid Arthritis, Ankylosing Spondylitis, Other Disease Types) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Interleukin Inhibitors Global Market Report 2024 – By Type (IL-17, IL-23, IL-1, IL-5, IL-6, Other Types), By Application (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, Other Applications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Pre Filled Syringes Global Market Report 2024 – By Type (Conventional Prefilled Syringes, Safety Prefilled Syringes), By Material (Glass Prefilled Syringes, Plastic Prefilled Syringes), By Design (Single-Chamber Prefilled Syringes, Dual- Chamber Prefilled Syringes, Customized Prefilled Syringes), By Application (Diabetes, Rheumatoid Arthritis, Anaphylaxis, Cancer, Thrombosis, Ophthalmology, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Musculoskeletal Disorders Drugs Global Market Report 2022 – By Type (Drugs For Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Microbiome Therapeutics Global Market Report 2022 – By Product (Probiotics, Prebiotics, Symbiotics, and Other Products), By Application (Inflammatory Bowel Disease, Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, and Other Applications), By Distribution Channel (Hospital Pharmacies, Drug Stores, Retail Pharmacies, and E-commerce Stores) – Market Size, Trends, And Global Forecast 2022-2026
View Report

Frequently Asked Questions

What is the definition of the arthritis monoclonal antibodies market?

Arthritis monoclonal antibodies refer to a class of sophisticated and useful biologic medicines used to treat rheumatoid arthritis and other immune-mediated inflammatory conditions. They inhibit the inflammatory protein interleukin-6, which reduces arthritis-related joint pain and swelling as well as other inflammation-related symptoms. In order to prevent the body from rejecting the new organ after surgery, they reduce the body's defence mechanism. For further insights on the arthritis monoclonal antibodies market, request a sample here

How will the arthritis monoclonal antibodies market drivers and restraints affect the arthritis monoclonal antibodies market dynamics? What forces will shape the arthritis monoclonal antibodies industry going forward?

The arthritis monoclonal antibodies market growth is aided by increasing prevalence of arthritis globally. However, some arthritis monoclonal antibodies market restraints include high cost of monoclonal antibodies. For further insights on the arthritis monoclonal antibodies market, request a sample here

What is the forecast market size or the forecast market value of the arthritis monoclonal antibodies market?

The arthritis monoclonal antibodies market is expected to reach $71.66 billion in 2027 at a rate of 7.4%. For further insights on the arthritis monoclonal antibodies market, request a sample here

How is the arthritis monoclonal antibodies market segmented?

The global arthritis monoclonal antibodies market is segmented as
1) By Drug: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima
2) By Application: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Other Applications
3) By End-Use: Hopitals, Research Institutes, Other End-Users
For further insights on the arthritis monoclonal antibodies market, request a sample here

Which region has the largest share of the arthritis monoclonal antibodies market? What are the largest region's market size and growth rate?

North America was the largest region in the arthritis monoclonal antibodies market in 2022. For detailed insights on the largest region's market size and growth rate, request a sample here.

Who are the major players in the arthritis monoclonal antibodies market?

Key competitors in the arthritis monoclonal antibodies market are, Johnson & Johnson, Roche, Novartis, Pfizer Inc, AbbVie Inc., Amgen Inc., Genentech, GSK, AstraZeneca PLC, Mylan N.V, Bristol Myers Squibb, Eli Lily and Company, Thermofischer Scientific, Sanofi, Novo Nordisk A/S, Daiichi Sankyo Company ltd., Seattle genetics, Teva pharmaceutical industries, Shanghi Junsi bioscience ltd, GenScript, Sigma-Aldrich Co. LLC, AbGenomics, ADC Therapeutics, Agensys, Alexion Pharmaceuticals, ALMAC Group, Ambrx, Astellas Pharma, Celgene, Celldex Therapeutics,. For further insights on the arthritis monoclonal antibodies market, request a sample here.

What are the key trends in the arthritis monoclonal antibodies market?

Major trends influencing the arthritis monoclonal antibodies market include development of therapeutic monoclonal antibody products which is becoming an indispensable tool in the development of the arthritis monoclonal antibody market. Monoclonal antibodies are more efficient than small molecules and peptides in the treatment of arthritis. These are target specific and have good efficiency for disease treatment. These improved treatment options are evident with the launch of a greater number of monoclonal antibody drugs for arthritis. For further insights on the arthritis monoclonal antibodies market, request a sample here.

What are the major opportunities in the arthritis monoclonal antibodies market? What are the strategies for the arthritis monoclonal antibodies market?

For detailed insights on the major opportunities and strategies in the arthritis monoclonal antibodies market, request a sample here.

How does the arthritis monoclonal antibodies market relate to the overall economy and other similar markets?

For detailed insights on arthritis monoclonal antibodies market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the arthritis monoclonal antibodies industry?

For detailed insights on the mergers and acquisitions in the arthritis monoclonal antibodies industry, request a sample here.

What are the key dynamics influencing the arthritis monoclonal antibodies market growth? SWOT analysis of the arthritis monoclonal antibodies market.

For detailed insights on the key dynamics influencing the arthritis monoclonal antibodies market growth and SWOT analysis of the arthritis monoclonal antibodies industry, request a sample here.